$SWX

Southwest Gas (SWX) Q2 2026 Earnings Call Transcript

Southwest Gas (SWX) discussed Q2 2026 progress on regulatory strategy across California, Nevada and Arizona. Nevada received intervenor testimony for a general rate case with a requested ~$74M annual revenue increase. California decision added ~$40M annual revenue and ~$9.7M incremental Q2 net income. Great Basin’s 2028 Expansion contracted demand to ~1 Bcf/day; 48-inch design lifts 2028 capex to ~$2.3B and incremental annual margin to ~$270M-$300M. Q2 adjusted EPS rose to $0.45 from $0.37.

Original reporting
Published Aug 12, 2026, 5:00 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 12, 2026, 5:11 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Southwest Gas (SWX) Q2 2026 Earnings Call Transcript — source image
Decision brief

The 30-second read

$SWXBullishMed
01

Why it matters

The call combines earnings datapoints (adjusted EPS $0.45 vs $0.37 prior year) with concrete regulatory outcomes (California incremental annual revenue and Nevada requested revenue increase) and project economics (contracted demand near 1 Bcf/day and higher estimated capex/margin).

02

Market read

Traders can update near-term expectations for earnings support from California’s decision and the timing of Nevada’s rebuttal/hearing and October 2026 effective date, while monitoring remaining cost-of-capital uncertainty.

03

What to watch

The 2028 expansion capex estimate ($2.3B) and FERC CPCN timing introduce execution and regulatory schedule risk that may offset near-term earnings support.

Relevance 7/10Novelty 6/10Timing: ahead of next week’s Nevada rebuttal filing and later-month California cost-of-capital decision

Background

Southwest Gas’ Q2 2026 earnings call focused on regulatory strategy across California, Nevada, and Arizona, plus progress on the Great Basin 2028 Expansion Project.

Company-level read

Ticker impact

$SWXBullishMedium confidence
Context

Southwest Gas disclosed Q2 2026 adjusted EPS of $0.45 and detailed regulatory updates, including California incremental revenue and Nevada rate-case progress.

Expected impact

Moderately positive bias for the stock, with volatility around the remaining California cost-of-capital decision and Nevada rebuttal/hearing timeline.

Evidence & confidence

The call provides multiple concrete datapoints: California decision driving ~$40M incremental annual revenue and ~$9.7M incremental net income recognized in Q2, Nevada requested annual revenue increase of ~$74M and an October 2026 effective-date path, plus a $2.3B 2028 expansion capex estimate tied to higher contracted demand.

Market effects

Reinforces the importance of state-by-state cost-of-capital and recovery mechanisms for US regulated utilities’ earnings trajectories.

California and Nevada regulatory milestones can influence regional natural gas utility sentiment and rate-case risk premia.

Limited direct global relevance; primarily impacts US regulated utility pricing and rate-case expectations.

Counterpoint

Even with incremental revenue, the remaining California cost-of-capital component and intervenor-driven ROE layers could still pressure earned returns versus expectations.

Key entities

  • Southwest Gas

    US natural gas utility subject of the earnings call, providing regulatory and project updates across its service territories.

  • Great Basin 2028 Expansion Project

    Pipeline expansion initiative with updated contracted demand, design changes, and revised capex and margin estimates.

Related articles

$SWXMed

Southwest Gas Q2 Earnings Call Highlights

Southwest Gas (NYSE:SWX) reported Q2 expense and income drivers, ending the quarter with about $270 million cash and nearly $1 billion liquidity. It cited rate-case progress in California, Nevada, and Arizona, including expected incremental revenue and net income, and discussed a Great Basin 2028 expansion. The company plans $1.25 billion capex in 2026 and expects $400 million utility debt.

$SWXMed

Southwest Gas Holdings, Inc. Q2 2026 Earnings Call Summary

Southwest Gas Holdings reported Q2 2026 results driven by lower HoldCo interest expense after debt repayment and improved Nevada regulatory outcomes. It received Nevada Triennial Resource Plan approval for $186 million of infrastructure investment and raised the Great Basin 2028 Expansion Project estimate to $2.3 billion, targeting $270 million to $300 million in incremental annual margin.

$SWXMed

Southwest Gas Holdings Reports Net Income In Q2; Reaffirms 2026 Guidance

Southwest Gas Holdings (SWX) reported Q2 net income of $42.1 million, versus a $40.2 million net loss in Q2 2025. EPS was $0.58 versus a loss of $0.56. Adjusted net income from continuing operations rose to $32.40 million, and adjusted EPS from continuing operations was $0.45. Regulated revenues were $358.2 million. The company reaffirmed its 2026 and long-term EPS guidance.

$SWXMed

Southwest Gas Holdings, Inc. (SWX): Results of Operations and Financial Condition

Southwest Gas Holdings, Inc. (SWX) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99 2 swx63026-earningsrelease.htm JUNE 2026 EARNINGS RELEASE Document Southwest Gas Holdings, Inc. Reports Second Quarter 2026 Financial Results, Reaffirms Full-Year 2026 Guidance Delivered 8.1% T welve-month-ended Utility ROE Great Basin Demand Raises 2028 Expansion Project C

$ATROMedAI 8/10

Why Astronics Stock Popped Today

Astronics (NASDAQ: ATRO) shares rose about 15.8% by 11:30 a.m. ET after the company reported Q2 results above analyst expectations. Analysts forecast EPS of $0.54 on $245.8M sales; Astronics posted $0.70 EPS on $260M sales. The firm guided Q3 sales to $265M-$275M and cited $780.6M backlog.

$KMDAMed

Kamada Ltd. Q2 2026 Earnings Call Summary

Kamada Ltd. reported Q2 2026 results driven by double-digit growth in its commercial portfolio, led by KEDRAB. Management reiterated 2026 revenue guidance of $200 million to $205 million and a 26% adjusted EBITDA margin. It expects plasma sales to start in Q4, supported by a 3-year $50 million supply deal, plus biosimilar expansion and M&A. CFO Chaime Orlev will leave end-2026.